MedWatch

Huge acquisition scores Novo Nordisk an FDA-ready treatment

Through acquiring Dicerna, Novo Nordisk is getting its hands on a drug candidate that is expected to be submitted for FDA approval during first quarter of 2022.

In around a year's time, Novo Nordisk may be able to enter a new market with an approved treatment under its belt, after its USD 3.3bn acquisition of Dicerna.

As well as knowledge and technology, Novo Nordisk is also taking over a number of drug candidates in the clinical phase, including the most advanced candidate, nedosiran, which is being developed as a treatment for primary hyperoxaluria, a rare condition characterized by recurring kidney and bladder stones. This candidate is expected to be submitted in the first quarter of 2022 for FDA approval, which can then spend up to ten months deliberating over whether the candidate can be authorized for use on the US market.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs